Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The suspect accused in the 2011 hit-and-run crash that killed former Kern High School District police chief Steve Alvidrez ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.